Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
340 Results for "
Integrin beta
" in MedChemExpress (MCE) Product Catalog:
Products (340)
340 Results for "Integrin beta" in MCE Product Catalog:
Cat. No.: HY-186079B
Target:
Research Areas:
Deethyl-emvistegrast TFA is a quinoline derivative and also a α4β7 integrin inhibitor. Deethyl-emvistegrast TFA is the hydrolytic product of Emvistegrast (HY-177080). Deethyl-emvistegrast TFA modulates inflammatory pathways. Deethyl-emvistegrast TFA can be used in research related to inflammatory bowel disease (Crohn's disease and ulcerative colitis) .
Cat. No.: HY-P1613A
CAS No.: 199807-33-5
Synonyms: Cyclo(RGDfV) TFA; C(RGDfV) TFA
Cat. No.: HY-W008859R
CAS No.: 67-30-1
Synonyms: Tetraiodothyroacetic acid (Standard); 3,3',5,5'-Tetraiodothyroacetic acid (Standard)
Cat. No.: HY-177331
CAS No.: 1259029-47-4
Target:
Research Areas:
BTT-3034, a sulfonamide derivative, is an α2β1 integrin inhibitor. BTT-3034 inhibits cell adhesion to rat tail collagen I with an EC50 of 160 nM and a corresponding Emaxof 86%. BTT-3034 inhibits collagen binding by an α2 variant carrying the conformationally activating E318W mutation .
Cat. No.: HY-186079A
Target:
Research Areas:
(S)-Deethyl-emvistegrast is the S-enantiomer of Deethyl-emvistegrast (HY-186079). Deethyl-emvistegrast is a quinoline derivative and also a α4β7 integrin inhibitor. It acts as the hydrolysis product of Emvistegrast (HY-177080). Deethyl-emvistegrast modulates inflammatory pathways and can be used in research related to inflammatory bowel diseases (Crohn's disease and ulcerative colitis) .
Cat. No.: HY-D2439
Cat. No.: HY-100133A
Purity: 96.18%
Cat. No.: HY-P5021
CAS No.: 756500-22-8
Synonyms: c(RGDfE)
Target:
Research Areas:
KBU2046 is an orally active transforming growth factor-β (TGF-β1) inhibitor. KBU2046 reduces integrin family protein expression, decreases Raf, RIPK1 and ERK phosphorylation to deactivate the ERK signaling pathway, and down-regulates genes linked to TGF-β1 maturation. KBU2046 suppresses tumor cell motility, impedes cancer invasion and metastasis, and inhibits human ESCC growth and metastasis in a murine model. KBU2046 can be used for the researches of triple-negative breast cancer and esophageal squamous cell carcinoma .
Cat. No.: HY-175593
CAS No.: 696628-90-7
Research Areas:
M6766 is a selective endoplasmic reticulum oxidoreductase 1α (ERO1α) inhibitor with an IC50 of 1.4 μM and a KD of 1.1 μM. M6766 also inhibits ERO1β with an IC50 of 7.2 μM. M6766 binds to the flavin adenine dinucleotide-binding pocket in ERO1α. M6766 inhibits granule secretion, αIIbβ3 integrin activation, Ca 2+ mobilization, and platelet aggregation. M6766 can be used for the research of neurological disease, such as ischemic stroke .
Cat. No.: HY-184578
Target:
Research Areas:
DOPE-PEG1000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG1000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-184578A
Target:
Research Areas:
DOPE-PEG2000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG2000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-184578B
Target:
Research Areas:
DOPE-PEG3400-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG3400-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-184578C
Target:
Research Areas:
DOPE-PEG5000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 5000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DOPE-PEG5000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-184579
Target:
Research Areas:
DMG-PEG1000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 1000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DMG-PEG1000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-184579A
Target:
Research Areas:
DMG-PEG2000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DMG-PEG2000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-184579B
Target:
Research Areas:
DMG-PEG3400-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 3400 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DMG-PEG3400-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
